SW48細胞 
	
		是否是腫瘤細胞:	1
	
	
		物種來源:	人
	
	
		生長狀態:	貼壁生長
	
	
		器官來源:	結腸
	
	
		運輸方式:	凍存運輸
	
	
		細胞形態:	上皮樣
	
	
		數量:	大量
	
	
		年限:	Dukes' type C, grade IV
	
	
		ATCC Number:	CCL-231?
	
	
		相關**:	大腸癌
	
	
		SW48細胞Designations:	SW48 [SW-48]
	
	
		Depositors:	 A Leibovitz
	
	
		Biosafety Level:	1
	
	
		Shipped:	frozen
	
	
		Medium & Serum:	See Propagation
	
	
		Growth Properties:	adherent
	
	
		Organism:	Homo sapiens
	
	
		Morphology:	epithelial
	
	
		
	
	
		Source:	Organ: colon
	
	
		Tumor Stage: Dukes' type C, grade IV
	
	
		Disease: colorectal adenocarcinoma
	
	
		Cellular Products:	carcinoembryonic antigen (CEA) 0.6 ng/10 exp6 cells/10 days; keratin
	
	
		Permits/Forms: SW48細胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
	
	
		Applications:	transfection host
	
	
		Tumorigenic:	Yes
	
	
		Antigen Expression:	HLA A32, A33, B27, B35; blood type AB; Rh+
	
	
		DNA Profile (STR):	Amelogenin: X
	
	
		CSF1PO: 9, 10
	
	
		D13S317: 11, 12
	
	
		D16S539: 11, 13
	
	
		D5S818: 10, 14
	
	
		D7S820: 9, 10
	
	
		THO1: 6, 9.3
	
	
		TPOX: 8
	
	
		vWA: 18, 20, 21
	
	
		SW48細胞Isoenzymes:	ES-D, 1
	
	
		G6PD, B
	
	
		PEP-D, 1
	
	
		PGD, A
	
	
		PGM1, 1
	
	
		PGM3, 1-2
	
	
		Age:	82 years
	
	
		Gender:	female
	
	
		Ethnicity:	Caucasian
	
	
		Comments:	CSAp negative (CSAp-).
	
	
		The cells are positive for keratin by immunoperoxidase staining.
	
	
		Propagation: SW48細胞ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
	
	
		Atmosphere: air, 100%
	
	
		Temperature: 37.0°C
	
	
		Subculturing:	Protocol:
	
	
		Culture never becomes 100% confluent. Remove and discard culture medium.
	
	
		Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
	
	
		Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
	
	
		Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
	
	
		Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
	
	
		To remove trypsin-EDTA solution, transfer cell suspension to a centrifuge tube and spin at approximately 125 xg for 5 to10 minutes.Discard supernatant and resuspend cells in fresh growth medium. Add appropriate aliquots of cell suspension to new culture vessels..
	
	
		Incubate cultures at 37?C.
	
	
		
	
	
		Subcultivation Ratio: SW48細胞A subcultivation ratio of 1:2 to 1:6 is recommended
	
	
		Medium Renewal: 1 to 2 times per week
	
	
		Preservation:	Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
	
	
		Storage temperature: liquid nitrogen vapor phase
	
	
		Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2008
	
	
		recommended serum:ATCC 30-2020
	
	
		References:	22140: . . In Vitro 8: 443, 1973.
	
	
		22147: Chen TR, et al. Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins. Cancer Genet. Cytogenet. 10: 351-362, 1983. PubMed: 6652615
	
	
		22260: Chen TR, et al. Karyotype consistency in human colorectal carcinoma cell lines established in vitro. Cancer Genet. Cytogenet. 6: 93-117, 1982. PubMed: 7104989
	
	
		22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
	
	
		23025: Leibovitz A, et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36: 4562-4569, 1976. PubMed: 1000501
	
	
		25093: Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res. 57: 488-494, 1997. PubMed: 9012479
	
	
		32265: Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066